These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31713653)

  • 1. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.
    Izumi K; Kanda J; Nishikori M; Arai Y; Ishikawa T; Yoshioka S; Ueda Y; Maeda T; Yonezawa A; Anzai N; Moriguchi T; Imada K; Akasaka T; Nohgawa M; Itoh M; Aiba A; Tsunemine H; Watanabe M; Kondo T; Takaori-Kondo A
    Ann Hematol; 2019 Dec; 98(12):2815-2823. PubMed ID: 31713653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
    Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
    Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
    Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
    Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
    Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
    Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
    Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
    Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
    Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
    Bento L; Gutiérrez A; Novelli S; Montoro J; Piñana JL; López-Corral L; Cabrero M; Martín-Sancho A; Gutiérrez-García G; Ortiz-Moscovich M; Bastos-Oreiro M; Dorado N; Pérez A; Hernani R; Ferrà C; Parody R; García-Cadenas I; Herrera P; Rodríguez G; Rodríguez N; Martín C; Yáñez L; Zanabili J; Varela MR; López-Godino O; Heras I; Español I; Martínez C; Pérez-Simón JA; Solano C; Sureda A; Sierra J; Sampol A; Caballero D;
    Bone Marrow Transplant; 2021 Aug; 56(8):1919-1928. PubMed ID: 33767400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.
    Loirat M; Chevallier P; Leux C; Moreau A; Bossard C; Guillaume T; Gastinne T; Delaunay J; Blin N; Mahé B; Dubruille V; Augeul-Meunier K; Peterlin P; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Mohty M; Moreau P; Le Gouill S
    Ann Oncol; 2015 Feb; 26(2):386-92. PubMed ID: 25392158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage Haploidentical Transplantation Using Low-dose ATG for Early Disease Relapse after First Allogeneic Transplantation: A Retrospective Single-center Review.
    Okamoto S; Matsuoka KI; Sakamoto M; Usui Y; Fujiwara Y; Kondo T; Tani K; Saeki K; Meguri Y; Asada N; Ennishi D; Nishimori H; Fujii K; Fujii N; Maeda Y
    Acta Med Okayama; 2019 Apr; 73(2):161-171. PubMed ID: 31015751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group.
    Watanabe M; Kanda J; Arai Y; Hishizawa M; Nishikori M; Ishikawa T; Imada K; Ueda Y; Akasaka T; Yonezawa A; Nohgawa M; Kitano T; Itoh M; Takeoka T; Moriguchi T; Yago K; Arima N; Anzai N; Watanabe M; Kondo T; Takaori-Kondo A;
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2346-2358. PubMed ID: 32738500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.
    Rashidi A; Ebadi M; Cashen AF
    Bone Marrow Transplant; 2016 Apr; 51(4):521-8. PubMed ID: 26726948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
    Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
    Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.